Arcutis Biotherapeutics (ARQT) vs Maravai LifeSciences (MRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Maravai LifeSciences (MRVI) has outperformed Arcutis Biotherapeutics (ARQT) over the past year, gaining 124.5% versus a gain of 17.5%. Over five years, ARQT leads with a +8.5% price change compared with -80.0% for MRVI. Arcutis Biotherapeutics is the larger company by market cap ($3.08 billion vs $2.67 billion), about 1.2 times the size.
Arcutis Biotherapeutics converts more of its revenue into profit, with a net margin of -4.3% versus -70.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARQT | MRVI |
|---|---|---|
| Share price | $24.49 | $7.21 |
| Market cap | $3.08B | $2.67B |
| 1-day change | +1.32% | -2.96% |
| YTD return | -16.77% | +128.62% |
| 1-year return | +17.50% | +124.47% |
| 5-year return | +8.48% | -79.97% |
| P/E ratio (TTM) | 111.32 | — |
| Forward P/E | 18.01 | — |
| EPS (TTM) | $0.22 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $376.07M | $185.74M |
| Revenue growth (YoY) | +91.34% | -28.34% |
| Net income (latest FY) | $-16.14M | $-130.77M |
| Gross margin | 90.24% | 18.30% |
| Operating margin | -3.25% | -115.89% |
| Net margin | -4.29% | -70.41% |
| 52-week high | $31.77 | $9.42 |
| 52-week low | $19.30 | $2.55 |
| Distance from 52-week high | -22.91% | -23.46% |
| Analyst consensus | none | buy |
| Avg. price target upside | +51.08% | +8.60% |
| Average volume | 2.22M | 3.33M |
| Shares outstanding | 125.69M | 148.99M |
| Employees | 354 | 415 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRVI has outperformed ARQT by 107.0 percentage points over the past year.
- Arcutis Biotherapeutics is more profitable, keeping -4.3 cents of every revenue dollar as net income versus -70.4 cents for Maravai LifeSciences.
- Arcutis Biotherapeutics grew revenue faster in its latest fiscal year (+91.34% vs -28.34%).
About Arcutis Biotherapeutics
ARQT stock →Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 415 employees
ARQT vs MRVI FAQ
Which is bigger, Arcutis Biotherapeutics or Maravai LifeSciences?
Arcutis Biotherapeutics (ARQT) is larger, with a market capitalization of $3.08B compared with $2.67B for Maravai LifeSciences (MRVI).
Which stock has performed better over the past year, ARQT or MRVI?
MRVI returned +124.47% over the past 12 months, compared with +17.50% for ARQT (price return, excluding dividends). Past performance does not predict future results.
Are Arcutis Biotherapeutics and Maravai LifeSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.